Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Kidney Int. 2017 Mar 6;92(1):201–213. doi: 10.1016/j.kint.2016.12.024

Figure 3.

Figure 3

Figure 3

Figure 3

Figure 3

High d-sp IFN-γ-producing T-cell alloreactivity measured 3 months prior to protocol biopsies predicted the advent of sc-TCMR at 6 months (n=101).

3a. Positive correlation between 3 and 6-mo d-sp IFN-γ producing T-cell frequencies (R=0.85, p<0.01).

3b. Venn diagram showing the relationship between 3 and 6-month ELISPOT.

3c. Three months prior to protocol biopsies, the assessment of circulating d-sp IFN-γ ELISPOT assay predicted the presence of 6-month sc-TCMR (AUC 0.711; 95% CI 0.595-0.827; p=0.009) showing 80% sensitivity, 65.1% specificity, 94.9% NPV and 28.6% PPV.

3d. Proportion of patients with 3-month d-sp IFN-γ T-cell alloreactivity and incidence of subsequent sc-TCMR at 6 months after transplantation. Twelve out of 15(80%) of patients developing sc-TCMR were highly alloreactive patients and 3/15(20%) were not; only 30/86 (34.8%) of patients without sc-TCMR were T-cell alloreactive, whereas 56/86(65.1%) were not, p=0.001.